ホーム › 腎臓がん（腎細胞がん） › イリノイ州

イリノイ州における腎臓がん（腎細胞がん）の臨床試験

イリノイ州内の拠点で、腎臓がん（腎細胞がん）に関する14件の研究が参加者を募集しています。

イリノイ州内の都市

公式研究テキスト（英語）

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NEO-811 Chicago Site, Zion

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/05更新 · NCT07300241

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

OSF Saint Anthony's Health Center, Alton
Rush-Copley Medical Center, Aurora
Advocate Outpatient Center - Aurora, Aurora
他54件

被験者募集中観察研究健康なボランティア歓迎

40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #26, Chicago

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Rush MD Anderson Cancer Center, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
Carle at The Riverfront, Danville
他12件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

City of Hope Chicago, City of Hope Cancer Center Chicago, Zion

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07594106

DESTINY-PANTUMOUR04

Research Site, Decatur

被験者募集中観察研究

18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Centralia Oncology Clinic, Centralia
Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
他25件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/18更新 · NCT05327686

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Memorial Hospital, Shiloh
Siteman Cancer Center - Shiloh, Shiloh
City Of Hope - Chicago, Zion

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/17更新 · NCT07227415

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Advocate Outpatient Center - Aurora, Aurora
Advocate Good Shepherd Hospital, Barrington
Illinois CancerCare-Bloomington, Bloomington
他53件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/02更新 · NCT06661720

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Xencor Investigative Site, Chicago
Xencor Investigative Site, Chicago

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/03更新 · NCT05433142

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Illinois CancerCare-Bloomington, Bloomington
Illinois CancerCare-Canton, Canton
Illinois CancerCare-Carthage, Carthage
他13件

被験者募集中第3相

18歳以上 · 全性別 · 2026/06/11更新 · NCT07383441

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

University of Chicago, Chicago

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/04/28更新 · NCT06413680

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Saint Anthony's Health, Alton
Rush - Copley Medical Center, Aurora
Advocate Good Shepherd Hospital, Barrington
他58件

被験者募集中第3相

18歳以上 · 全性別 · 2025/09/09更新 · NCT04510597

Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Loyola University Medical Center, Maywood

被験者募集中観察研究

18歳以上 · 全性別 · 2025/03/19更新 · NCT05728957

ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。